SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Allora is a decentralized intelligence network that makes artificial intelligence more adaptive, collaborative, and efficient. The platform combines and coordinates thousands of specialized AI models in real time to produce superior inferences for users and applications. By enabling anyone to contribute models, data, or validation, Allora creates a self-improving market for intelligence that powers agents, DeFi systems, and AI applications across chains.

Allora

Allora is capturing trader attention due to its position in the AI-optimization sector, with bullish participants betting on sustained momentum and potential technical breakouts. While some community members view the price volatility as a sign of a pump-and-dump scheme, others highlight the project's limited circulating supply and incoming project updates as key catalysts for growth.

Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The firm investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

Unicycive Therapeutics Inc

Unicycive Therapeutics is trending as investors weigh the company's path toward NDA resubmission following a manufacturing-related delay, with community sentiment split between frustration over share dilution and confidence in the long-term potential of its OLC drug candidate. The core discussion remains focused on the upcoming regulatory updates, the company's cash runway, and whether management can regain credibility through a successful Type A meeting with the FDA.

iShares Inc. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

The iShares MSCI South Korea ETF is experiencing significant volatility driven by massive spikes in put option interest as investors hedge against a potential market correction following a sharp single-session drop. While the community is debating whether this signals an AI-driven bubble ready to burst or a dip-buying opportunity, the broader discourse remains focused on the critical role of South Korean semiconductor giants like Samsung and SK Hynix in sustaining the global AI infrastructure cycle.

Direxion Shares ETF Trust - Direxion Daily MSCI South Korea Bull 3X ETF

Direxion Daily South Korea Bull 3X Shares

The KORU ETF is attracting intense community attention as traders debate the sustainability of its parabolic rally, which is largely driven by South Korea's dominant memory chip manufacturers and significant volatility inherent in a 3x leveraged fund. While some participants are aggressively scaling into positions to capitalize on structural AI memory demand, others warn of significant downside risk from rapid leverage decay and the potential for a sharp correction in the broader Korean market.

Chip

CHIP is seeing significant community debate as bulls highlight its role in financing the AI compute infrastructure sector, while bears criticize persistent price declines and concerns over token supply. Traders are actively speculating on the potential for a short squeeze driven by the token's high volume and volatility, as market participants weigh the project's utility against ongoing sell pressure.

ViaSat, Inc. engages in providing communications technologies and services. It operates through the Communication Services and Defense and Advanced Technologies business segments. The Communication Services business segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets. The Defense and Advanced Technologies business segment develops and offers a diverse array of resilient, vertically integrated solutions to government and commercial customers, leveraging the company’s technical competencies in encryption, cyber security, tactical gateways, modems, and waveforms. The company was founded by Mark D. Dankberg and Mark J. Miller on May 1, 1986 and is headquartered in Carlsbad, CA.

Viasat, Inc.

Viasat is trending as the market weighs the company's potential split of its defense business against broader sector volatility, with community debate centered on whether to trade the tactical volatility or hold for long-term structural execution. While some participants are wary of its heavy debt load and competition, the stock remains a focal point due to its expanding government and military contract footprint and recent speculative interest regarding portfolio strategic reviews.

Onto Innovation, Inc. engages in the business of designing, development, manufacturing, and support of high-performance control metrology, defect inspection, lithography, and data analysis systems used by microelectronics device manufacturers. It is also involved in providing process and yield management solutions used in bare silicon wafer production and wafer processing facilities. The company was founded in 1940 and is headquartered in Wilmington, MA.

Onto Innovation Inc.

Onto Innovation is gaining significant traction within the semiconductor sector as investors monitor its critical role in advanced packaging and metrology for AI-driven chip architectures. The community is actively discussing the stock's resilient technical structure and its strategic positioning in the evolving high-bandwidth memory (HBM) supply chain, with many highlighting potential upside driven by long-term data center expansion.

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK Plc - ADR

Glaxosmithkline plc - ADR

GlaxoSmithKline (GSK) is capturing community attention as investors anticipate a potential asset sale or strategic move involving Spero Therapeutics (SPRO) to capitalize on the upcoming tebipenem HBr FDA decision. Discussions are heavily focused on the high likelihood of a corporate metamorphosis for SPRO through a potential reverse merger or deal that would clear GSK's royalty obligations while expanding their oncology footprint in the Boston biotech corridor.

Eaton Corp. Plc is a power management company, which provides energy-efficient solutions for electrical, hydraulic, and mechanical power. It operates through the following segments: Electrical Americas and Electrical Global; Aerospace, Vehicle, and eMobility. The Electrical Americas and Electrical Global segments engage in sales contracts for electrical components, industrial components, power distribution and assemblies, residential products, single and three phase power quality, wiring devices, circuit protection, utility power distribution, power reliability equipment, and service. The Aerospace segment supplies aerospace fuel, hydraulics, and pneumatic systems for commercial and military use. The Vehicle segment deals with the design, manufacture, marketing, and supply of drivetrain and powertrain systems and critical components that reduce emissions and improve fuel economy, stability, performance and safety of cars, light trucks and commercial vehicles. The eMobility segment designs, manufactures, markets, and supplies electrical and electronic components and systems that improve the power management and performance of both on-road and off-road vehicles. The company was founded in 1911 and is headquartered in Dublin, Ireland.

Eaton Corporation plc

Eaton Corporation is trending as investors focus on its critical role in providing electrical infrastructure for the AI data center supercycle, with the community highlighting its massive backlog and role in solving power and thermal bottlenecks. Discussion is currently fueled by speculative institutional trading activity and the company's strategic positioning within the broader electrification and grid modernization theme.

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Neurocrine Biosciences, Inc.

Neurocrine Biosciences is gaining investor attention behind strong Q1 sales growth from INGREZZA and the launch of CRENESSITY, alongside active discussions regarding a rare-disease acquisition strategy. The community remains focused on the company's solid fundamentals and ongoing pipeline execution as it attempts to break through recent technical resistance levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

J&J Stock Gains Nearly 12% Year to Date: Buy, Sell or Hold Now?

JNJ is up nearly 12% YTD as strong oncology drug growth, MedTech demand and pipeline advances help offset Stelara patent-loss pressure.

J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?

JNJ's diversified pharma and MedTech growth, pipeline progress and stronger 2026 outlook give it an edge over PFE.

J&J's Pipeline Progress & New Drugs Promise Stronger Long-Term Growth 

J&J's expanding pipeline, new drug approvals and rising sales from cancer medicines are expected to fuel growth.

Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategy

JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimilar pressure.

Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Expected to Rise, Wedbush Analyst Says

Wedbush upped their target price on shares of Protagonist Therapeutics from $112.00 to $118.00 and gave the stock an 'outperform' rating in a research report on Wednesday...

Protagonist Therapeutics (NASDAQ:PTGX) Posts Earnings Results, Beats Expectations By $0.70 EPS

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported $0.05 earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.70. The company had revenue of $56.37 million for the quarter, compared to...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Moderate Buy" from Analysts

Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) has received an average recommendation of "Moderate Buy" from the fifteen ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a ho...

331,164 Shares in Protagonist Therapeutics, Inc. $PTGX Bought by Jennison Associates LLC

Jennison Associates LLC bought a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 331,164 shares of the company's stock, v...

M&T Bank Corp Acquires New Holdings in Protagonist Therapeutics, Inc. $PTGX

M&T Bank Corp acquired a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 11,207 shares of the company's stock, valued at approximately $979,000. Other large investors ha...

Pictet Asset Management Holding SA Has $46.26 Million Stock Position in Protagonist Therapeutics, Inc. $PTGX

Pictet Asset Management Holding SA lessened its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 35.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 529,631 shares o...

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Current Price	$97.38
Prev Close	$102.79
Open	$103.14
Dividend Yield	0.00%
50-Day Moving Average	$101.22
Beta	0.54
Avg. Volume	519,070.92
PE Ratio	-53.99

52-Week High	$107.84
52-Week Low	$49.38
Market Capitalization	$6.26B
EPS (Annual)	-$2.05
Price to Book	9.54
Revenue Per Employee	$348,606.06

PTGXProtagonist Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PTGX News